Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:57 AM
Ignite Modification Date:
2025-12-25 @ 3:57 AM
NCT ID:
NCT00215202
Eligibility Criteria:
Inclusion Criteria:
* Subject must be able to provide informed consent
* Subject must be 18 years of age or older
* Subject must have histologically confirmed ACC by Department of Pathology at Dartmouth Hitchcock Medical Center
* Subject must have inoperable disease
* Subject must have received some form of systemic therapy prior to enrolling in the study
Exclusion Criteria:
* known severe hypersensitivity to Iressa
* other co-existing malignancies diagnosed within the last five years except basal cell cancer or cervical cancer in situ
* any unresolved CTC grade 2 toxicity from previous anticancer therapy (except alopecia)
* absolute neutrophil count less than 1.5 x 1,000,000,000 per liter
* platelets less than 20 x 1,000,000,000 per liter
* severe uncontrolled systemic disease
* pregnancy\\breastfeeding
* women who are fertile and not willing to practice abstinence or contraception
* use of phenytoin, carbamazepine, rifampicin, barbiturates, or St. John's Wort
* treatment with a non-approved or investigational drug within 28 days before Day 1 of study treatment
* prior use of ZD1839 (Iressa) or any other anti-EGFR therapies
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00215202
Study Brief:
Protocol Section:
NCT00215202